A California startup is putting a new spin on a now-familiar idea: using RNA as the foundation of a new therapy.
Cancer-focused biotech Replicate Bioscience is hoping to take the same technology that underpins the Covid-19 vaccines from Moderna and Pfizer — with a bit of a scientific twist — and use it to help the body’s own cells attack cancer cells. The company is “relaunching” this week with what its key investor’s head of communications calls a “light rebranding;” it accompanies a $40 million Series A led by Apple Tree Partners.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
